Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.35 |
| ▸ | BMP4 | P12644 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756933 | 0.86 | ADRB2 (0.45) | NCF1ADRB2KCNH2TGFBR1 | |
| SCHEMBL856282 | 0.82 | CREBBP (0.47) | NCF1ADRB2PRMT5WDR77ACVR1 | |
| SCHEMBL861742 | 0.71 | CREBBP (0.45) | NCF1ADRB2ACVR1KCNH2TGFBR1 | |
| SCHEMBL859066 | 0.69 | CREBBP (0.47) | — | |
| SCHEMBL855964 | 0.67 | CREBBP (0.45) | NCF1ADRB2KCNH2PIK3R2 | |
| SCHEMBL858502 | 0.66 | CREBBP (0.50) | NCF1ADRB2ACVR1KCNH2TGFBR1 | |
| SCHEMBL856423 | 0.66 | FAAH (0.46) | NCF1ADRB2PRMT5 | |
| SCHEMBL13056560 | 0.66 | CREBBP (0.52) | NCF1ADRB2KCNH2 | |
| SCHEMBL10268352 | 0.65 | NCF1 (0.67) | NCF1ADRB2KCNH2 | |
| SCHEMBL900231 | 0.65 | NCF1 (1.00) | NCF1ADRB2ACVR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NCF1 3080/4885ADRB2 948/4885PRMT5 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.